Clinical Trial

rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia

Name: rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia — clinical trial record (NCT07653581)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.

Trial Details

NCT Number	NCT07653581
Lead Sponsor	Peking Union Medical College Hospital
Conditions	Lower-risk Myelodysplastic Syndromes
Enrollment	78 participants
Start Date	2026-06
Primary Completion	2028-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-17